Study Details

Relative Bioavailability study of enzalutamide in Prostate Cancer Patients

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred). ID

The unique identification code given to each clinical study upon registration at

Astellas Study ID

The unique identification code given by the study sponsor.


EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).



Prostate Cancer, Other


These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1


18 Years - N/A






A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


Trial Dates

Nov 2012 - Oct 2013


None (Open Label)

Enrollment number


A Phase I, open-label, randomized, parallel, relative bioavailability study comparing a capsule and a tablet formulation of Enzalutamide following multiple once daily doses of 160 mg Enzalutamide in male subjects with prostate cancer

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for Relative Bioavailability study of enzalutamide in Prostate Cancer Patients? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.


University of Chicago Medical Center

Chicago, United States, 60637

University of Pittsburgh Medical Center

Pittsburgh, United States, 15232

South Texas Accelerated Research Therapeutics

San Antonio, United States, 78229

University of Colorado - Anschutz Medical Campus

Denver, United States, 80045